Abuse-resistant amphetamine prodrugs

• US 7,662,788 B2
• Filed: 08/29/2008
• Issued: 02/16/2010
• Est. Priority Date: 02/22/2002
• Status: Expired due to Term

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Shire LLC (Shire plc)
• Inventors: Paul, Bernhard J., Piccariello, Thomas, Bishop, Barney, Krishnan, Suma, Verbicky, Christopher A., Oberlender, Robert, Mickle, Travis, Moncrief, James Scott, Lauderback, Christopher
• Primary Examiner(s): AUDET, MAURY A
• Application Number:
  US12/201,866
• Publication Number:
  US 20090137674A1
• Time in Patent Office: 536 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 47/542 Carboxylic acids, e.g. a fatty acid or an amino acid
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/26 Psychostimulants, e.g. nicotine, cocaine
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/34 Tobacco-abuse
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 237/06 having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• CPC Class Codes: Y10S 436/901 Drugs of abuse, e.g. narcotics, amphetamine
• CPC Class Codes: Y10T 436/173845 : Amine and quaternary ammonium

Abstract

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Claims

1. A method of decreasing abuse of amphetamines or salts thereof, in a subject in need thereof, said method comprising supplying said amphetamine to said subject in the form of L-lysine-d-amphetamine or a salt thereof.

2. A method as defined in claim 1, wherein said subject is an adult human.

3. A method as defined in claim 1, wherein said subject is a human who is not an adult.

4. A method as defined in claim 1, wherein said L-lysine-d-amphetamine is in the form of a salt.

5. A method as defined in claim 4, wherein said salt is a mesylate salt.

6. A method as defined in claim 5, wherein said salt is a dimesylate salt.

7. A method as defined in claim 4, wherein said salt is a hydrochloride salt.

8. A method as defined in claim 1, wherein said subject suffers from attention deficit hyperactivity disorder and said L-lysine-d-amphetamine or salt thereof is supplied in a dosage form in which the amount of said L-lysine-d-amphetamine or salt thereof is an attention deficit hyperactivity disorder treatment effective amount.

9. A method as defined in claim 8, wherein said amount is from about 2.5 to about 500 mg.

10. A method as defined in claim 9, wherein said amount is from about 5 to about 500 mg.

11. A method as defined in claim 10, wherein said amount is from about 10 to about 100 mg.

12. A method as defined in claim 11, wherein said amount is from 25 to 75 mg.

13. A method as defined in claim 12, wherein said amount is 30 mg.

14. A method as defined in claim 12, wherein said amount is 50 mg.

15. A method as defined in claim 12, wherein said amount is 70 mg.

16. A method as defined in claim 1, wherein said L-lysine-d-amphetamine or salt thereof is in a dosage form selected from the group consisting of a tablet, capsule, caplet, oral solution, and oral suspension.

17. A method as defined in claim 16, wherein said dosage form further comprises a member selected from the group consisting of lubricants, hydrophilic polymers, water-insoluble polymers, gums, modified cellulosic substances, colorants, binders, glidants, surface active agents, preservatives, stabilizers, excipients, plasticizers, adhesives, bulking substances, disintegrants, sweeteners, buffers, adsorbants, diluents, thickeners, wetting agents, humectants, antioxidants, or any combination of any of the foregoing.

18. A method as defined in claim 16, wherein said dosage form further comprises microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

19. A method as defined in claim 18, wherein said dosage form further comprises from about 40% to about 90% by weight of microcrystalline cellulose, from about 1% to about 10% by weight of croscarmellose sodium, and less than about 5% by weight of magnesium stearate.

20. A method of treating attention deficit hyperactivity disorder, in a patient intent on taking an amphetamine or a salt thereof inconsistent with the manufacturer'"'"'s instructions, said method comprising supplying the amphetamine in the form of L-lysine-d-amphetamine or a salt thereof.

21. A method as defined in claim 20, wherein said L-lysine-d-amphetamine is in the form of a salt.

22. A method as defined in claim 21, wherein said salt is a mesylate salt.

23. A method as defined in claim 22, wherein said salt is a dimesylate salt.

24. A method as defined in claim 20, wherein said salt is a hydrochloride salt.

25. A method of treating attention deficit hyperactivity disorder with an amphetamine, in a patient prone to amphetamine abuse, said method comprising supplying said amphetamine in the form of L-lysine-D-amphetamine or a salt thereof.

26. A method as defined in claim 25, wherein said L-lysine-d-amphetamine is in the form of a salt.

27. A method as defined in claim 26, wherein said salt is a mesylate salt.

28. A method as defined in claim 27, wherein said salt is a dimesylate salt.

29. A method as defined in claim 26, wherein said salt is a hydrochloride salt.

30. A method of decreasing abuse of amphetamines or salts thereof, in a subject in need thereof, said method comprising administering said amphetamine to said subject in the form of L-lysine-d-amphetamine or a salt thereof.

31. A method as defined in claim 30, wherein said subject is an adult human.

32. A method as defined in claim 30, wherein said subject is a human who is not an adult.

33. A method as defined in claim 30, wherein said L-lysine-d-amphetamine is in the form of a salt.

34. A method as defined in claim 33, wherein said salt is a mesylate salt.

35. A method as defined in claim 34, wherein said salt is a dimesylate salt.

36. A method as defined in claim 33, wherein said salt is a hydrochloride salt.

37. A method as defined in claim 30, wherein said subject suffers from attention deficit hyperactivity disorder.

38. A method as defined in claim 30, wherein said L-lysine-d-amphetamine or salt thereof is in a dosage form selected from the group consisting of a tablet, capsule, caplet, oral solution, and oral suspension.

39. A method of treating attention deficit hyperactivity disorder, in a patient intent on taking an amphetamine or a salt thereof inconsistent with the manufacturer'"'"'s instructions, said method comprising administering the amphetamine in the form of L-lysine-d-amphetamine or a salt thereof.

40. A method as defined in claim 39, wherein said L-lysine-d-amphetamine is in the form of a salt.

41. A method as defined in claim 40, wherein said salt is a mesylate salt.

42. A method as defined in claim 41, wherein said salt is a dimesylate salt.

43. A method as defined in claim 40, wherein said salt is a hydrochloride salt.

44. A method of treating attention deficit hyperactivity disorder with an amphetamine, in a patient prone to amphetamine abuse, said method comprising administering said amphetamine in the form of L-lysine-d-amphetamine or a salt thereof.

45. A method as defined in claim 44, wherein said L-lysine-d-amphetamine is in the form of a salt.

46. A method as defined in claim 45, wherein said salt is a mesylate salt.

47. A method as defined in claim 46, wherein said salt is a dimesylate salt.

48. A method as defined in claim 45, wherein said salt is a hydrochloride salt.